JPWO2023194271A5 - - Google Patents

Info

Publication number
JPWO2023194271A5
JPWO2023194271A5 JP2024547780A JP2024547780A JPWO2023194271A5 JP WO2023194271 A5 JPWO2023194271 A5 JP WO2023194271A5 JP 2024547780 A JP2024547780 A JP 2024547780A JP 2024547780 A JP2024547780 A JP 2024547780A JP WO2023194271 A5 JPWO2023194271 A5 JP WO2023194271A5
Authority
JP
Japan
Prior art keywords
antibody
dose
pharmaceutical composition
subject
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510490A (ja
JP2025510490A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/058605 external-priority patent/WO2023194271A1/en
Publication of JP2025510490A publication Critical patent/JP2025510490A/ja
Publication of JP2025510490A5 publication Critical patent/JP2025510490A5/ja
Publication of JPWO2023194271A5 publication Critical patent/JPWO2023194271A5/ja
Pending legal-status Critical Current

Links

JP2024547780A 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン Pending JP2025510490A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
EP22166586.2 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (3)

Publication Number Publication Date
JP2025510490A JP2025510490A (ja) 2025-04-15
JP2025510490A5 JP2025510490A5 (https=) 2026-04-03
JPWO2023194271A5 true JPWO2023194271A5 (https=) 2026-04-03

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547780A Pending JP2025510490A (ja) 2022-04-04 2023-04-03 抗ｃ５抗体クロバリマブの使用によるギラン・バレー症候群の治療または予防のための投薬量および投与レジメン

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Similar Documents

Publication Publication Date Title
JP2023002544A5 (https=)
JP2024174927A5 (https=)
JP2013543501A5 (https=)
JP2025172841A5 (https=)
JP2025020134A5 (https=)
JP2024174962A5 (https=)
JP2021113190A5 (https=)
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
JP2024069230A5 (https=)
IL320562A (en) Cancer treatment methods
JP2019519584A5 (https=)
JP2005514414A5 (https=)
RU2003125274A (ru) Применение флумазенила в производстве лекарства для лечения алкогольной зависимости
JPWO2021224499A5 (https=)
JPWO2023194271A5 (https=)
JPWO2023194273A5 (https=)
JP2025060703A5 (https=)
RU2024129212A (ru) Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба
RU2024129928A (ru) Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба
JP2005529152A5 (https=)
IL317954A (en) Treatment of hematological malignancies with galectin-9 inhibitory antibodies
Huang et al. Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study
JPWO2023095510A5 (https=)
JPWO2022198192A5 (https=)
RU2065748C1 (ru) Способ лечения хронических стафилодермий